Page last updated: 2024-12-08

satavaptan

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

satavaptan: a vasopressin V2 receptor antagonist; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID158348
CHEMBL ID4283439
CHEBI ID194402
SCHEMBL ID3868028
SCHEMBL ID1650011
MeSH IDM0270107

Synonyms (41)

Synonym
4-{[(1s,4s)-5'-ethoxy-4-[2-(4-morpholinyl)ethoxy]-2'-oxospiro[cyclohexane-1,3'-indol]-1'(2'h)-yl]sulfonyl}-3-methoxy-n-(2-methyl-2-propanyl)benzamide
[3h]sr 121463a
gtpl2199
[3h]-sr121463a
gtpl2234
sr-121463b
sr-121463f
satavaptan
sr-121463
sr-121463a
aquilda
sr121463a
CHEBI:194402
satavaptanum
185913-78-4
sr 121463
n-tert-butyl-4-[5'-ethoxy-4-(2-morpholin-4-ylethoxy)-2'-oxospiro[cyclohexane-1,3'-indole]-1'-yl]sulfonyl-3-methoxybenzamide
sr121463
sr 121463a
sr121463b
benzamide, n-(1,1-dimethylethyl)-4-((5'-ethoxy-4-(2-(4-morpholinyl)ethoxy)-2'-oxospiro(cyclohexane-1,3'-(3h)indol)-1'(2'h)-yl)sulfonyl)-3-methoxy-, cis-
unii-ajs8s3p31h
1-(4-(n-tert-butylcarbamoyl)-2-methoxybenzenesulfonyl)-5-ethoxy-3-spiro(4-(2-morpholinoethoxy)cyclohexane)indoline-2-one, phosphate monohydrate cis-isomer
ajs8s3p31h ,
1-(4-(n-tert-butylcarbamoyl)-2-methoxybenzenesulfonyl)-5-ethoxy-3-spiro-(4-(2-morpholinoethoxy)cyclohexane)indol-2-one fumarate
satavaptan [inn]
SCHEMBL3868028
benzamide, n-(1,1-dimethylethyl)-4-((cis-5'-ethoxy-4-(2-(4-morpholinyl)ethoxy)-2'-oxospiro(cyclohexane-1,3'-(3h)indol)-1'(2'h)-yl)sulfonyl)-3-methoxy-
n-tert-butyl-4-(((1s,4s)-5'-ethoxy-4-(2-morpholin-4-ylethoxy)-2'-oxospiro(cyclohexane-1,3'-indol)-1'(2'h)-yl)sulfonyl)-3-methoxybenzamide
satavaptan [mart.]
satavaptan [who-dd]
SCHEMBL1650011
DB14923
SB19720
CHEMBL4283439 ,
n-tert-butyl-4-[5/'-ethoxy-4-(2-morpholin-4-ylethoxy)-2/'-oxospiro[cyclohexane-1,3/'-indole]-1/'-yl]sulfonyl-3-methoxybenzamide
bdbm50469545
n-tert-butyl-4-{5'-ethoxy-4-[2-(morpholin-4-yl)ethoxy]-2'-oxospiro[cyclohexane-1,3'-indole]-1'(2'h)-sulfonyl}-3-methoxybenzamide
DTXSID60870165
GLXC-15075
AKOS040749404

Research Excerpts

Overview

Satavaptan (SR121463) is a vasopressin V2 receptor antagonist. Has been shown to improve hyponatremia in patients with cirrhosis, congestive heart failure, and syndrome of inappropriate antidiuresis.

ExcerptReferenceRelevance
"Satavaptan (SR121463) is a vasopressin V2 receptor antagonist that has been shown to improve hyponatremia in patients with cirrhosis, congestive heart failure, and syndrome of inappropriate antidiuresis. "( Global analysis of the effects of the V2 receptor antagonist satavaptan on protein phosphorylation in collecting duct.
Hoffert, JD; Knepper, MA; Pisitkun, T; Saeed, F; Wilson, JL, 2014
)
2.09

Effects

ExcerptReferenceRelevance
"Satavaptan has the potential to reduce recurrence of ascites after a large volume paracentesis at doses from 5 to 25mg in cirrhotic patients with ascites."( Effects of a selective vasopressin V2 receptor antagonist, satavaptan, on ascites recurrence after paracentesis in patients with cirrhosis.
Angeli, P; Bernardi, M; Gines, P; Gow, P; Horsmans, Y; Minini, P; Watson, H; Wong, F, 2010
)
2.05

Treatment

Satavaptan treatment was associated with a decrease in ascites (mean change in body weight was -0.36 kg for placebo vs. -1.68 kg for the 5 mg, 12.5 mg, and 25 mg doses, respectively; P = 0.05 for a dose-effect relationship overall)

ExcerptReferenceRelevance
"Satavaptan treatment was associated with improved control of ascites, as indicated by a reduction in body weight (mean change at Day 14 was +0.49 kg [+/-4.99] for placebo versus +0.15 kg [+/-4.23], -1.59 kg [+/-4.60] and -1.68 kg [+/-4.98] for the 5 mg, 12.5 mg, and 25 mg doses, respectively; P = 0.05 for a dose-effect relationship overall) and a parallel reduction in abdominal girth."( Effects of satavaptan, a selective vasopressin V(2) receptor antagonist, on ascites and serum sodium in cirrhosis with hyponatremia: a randomized trial.
del Arbol, LR; Ginès, P; Milutinovic, S; Olteanu, D; Watson, H; Wong, F, 2008
)
1.46
"Satavaptan treatment was associated with a decrease in ascites (mean change in body weight was -0.36 kg (+/-3.03) for placebo vs. "( Clinical trial: short-term effects of combination of satavaptan, a selective vasopressin V2 receptor antagonist, and diuretics on ascites in patients with cirrhosis without hyponatraemia--a randomized, double-blind, placebo-controlled study.
Bruha, R; Dudley, F; Ginès, P; Terg, R; Watson, H; Wong, F; Zarski, JP, 2010
)
2.05

Toxicity

ExcerptReferenceRelevance
" Overall, the rate of any treatment-related adverse events, serious treatment-related events and treatment-related events leading to permanent discontinuation of treatment did not differ significantly between the treatment groups."( Satavaptan for the management of ascites in cirrhosis: efficacy and safety across the spectrum of ascites severity.
Badalamenti, S; Bernardi, M; Gerbes, A; Ginès, P; Vilstrup, H; Watson, H; Wong, F, 2012
)
1.82

Bioavailability

ExcerptReferenceRelevance
" After acute and chronic administration to rats, dogs or healthy human volunteers, SR121463 was well absorbed and well tolerated."( An overview of SR121463, a selective non-peptide vasopressin V(2) receptor antagonist.
Serradeil-Le Gal, C, 2001
)
0.31

Dosage Studied

ExcerptRelevanceReference
" Thus, in absence of cystic changes, reduced Pkd1 gene dosage is associated with a syndrome of inappropriate antidiuresis (positive water balance) reflecting decreased intracellular Ca(2+) concentration, decreased activity of RhoA, recruitment of AQP2 in the CD, and inappropriate expression of AVP in the brain."( PKD1 haploinsufficiency causes a syndrome of inappropriate antidiuresis in mice.
Ahrabi, AK; Caron, N; Devuyst, O; Horie, S; Nielsen, S; Raufaste, D; Serradeil-Le Gal, C; Terryn, S; Valenti, G; Verbavatz, JM, 2007
)
0.34
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (1)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Vasopressin V1a receptorHomo sapiens (human)Ki1.62650.00020.62357.0300AID1409546; AID1409547
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (28)

Processvia Protein(s)Taxonomy
maternal aggressive behaviorVasopressin V1a receptorHomo sapiens (human)
positive regulation of systemic arterial blood pressureVasopressin V1a receptorHomo sapiens (human)
generation of precursor metabolites and energyVasopressin V1a receptorHomo sapiens (human)
activation of phospholipase C activityVasopressin V1a receptorHomo sapiens (human)
positive regulation of cytosolic calcium ion concentrationVasopressin V1a receptorHomo sapiens (human)
negative regulation of female receptivityVasopressin V1a receptorHomo sapiens (human)
grooming behaviorVasopressin V1a receptorHomo sapiens (human)
blood circulationVasopressin V1a receptorHomo sapiens (human)
positive regulation of cell population proliferationVasopressin V1a receptorHomo sapiens (human)
positive regulation of heart rateVasopressin V1a receptorHomo sapiens (human)
positive regulation of glutamate secretionVasopressin V1a receptorHomo sapiens (human)
myotube differentiationVasopressin V1a receptorHomo sapiens (human)
calcium-mediated signalingVasopressin V1a receptorHomo sapiens (human)
telencephalon developmentVasopressin V1a receptorHomo sapiens (human)
positive regulation of cell growthVasopressin V1a receptorHomo sapiens (human)
positive regulation of prostaglandin biosynthetic processVasopressin V1a receptorHomo sapiens (human)
positive regulation of cellular pH reductionVasopressin V1a receptorHomo sapiens (human)
social behaviorVasopressin V1a receptorHomo sapiens (human)
cellular response to water deprivationVasopressin V1a receptorHomo sapiens (human)
maternal behaviorVasopressin V1a receptorHomo sapiens (human)
sperm ejaculationVasopressin V1a receptorHomo sapiens (human)
response to corticosteroneVasopressin V1a receptorHomo sapiens (human)
negative regulation of transmission of nerve impulseVasopressin V1a receptorHomo sapiens (human)
transport across blood-brain barrierVasopressin V1a receptorHomo sapiens (human)
G protein-coupled receptor signaling pathwayVasopressin V1a receptorHomo sapiens (human)
positive regulation of vasoconstrictionVasopressin V1a receptorHomo sapiens (human)
cellular response to hormone stimulusVasopressin V1a receptorHomo sapiens (human)
regulation of systemic arterial blood pressure by vasopressinVasopressin V1a receptorHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (6)

Processvia Protein(s)Taxonomy
vasopressin receptor activityVasopressin V1a receptorHomo sapiens (human)
protein kinase C bindingVasopressin V1a receptorHomo sapiens (human)
protein bindingVasopressin V1a receptorHomo sapiens (human)
peptide hormone bindingVasopressin V1a receptorHomo sapiens (human)
V1A vasopressin receptor bindingVasopressin V1a receptorHomo sapiens (human)
peptide bindingVasopressin V1a receptorHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (3)

Processvia Protein(s)Taxonomy
endosomeVasopressin V1a receptorHomo sapiens (human)
plasma membraneVasopressin V1a receptorHomo sapiens (human)
endocytic vesicleVasopressin V1a receptorHomo sapiens (human)
plasma membraneVasopressin V1a receptorHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (13)

Assay IDTitleYearJournalArticle
AID1409546Displacement of [125I]OH-Phpa-LVA from human V1A receptor expressed in CHO cells after 4 hrs by gamma counter analysis2018Journal of medicinal chemistry, 11-21, Volume: 61, Issue:22
Receptor-Ligand Interaction Measured by Inductively Coupled Plasma Mass Spectrometry and Selenium Labeling.
AID1409547Displacement of [Se-Se]-AVP from human V1A receptor expressed in CHO cells after 4 hrs by RP-LC-ICPMS analysis2018Journal of medicinal chemistry, 11-21, Volume: 61, Issue:22
Receptor-Ligand Interaction Measured by Inductively Coupled Plasma Mass Spectrometry and Selenium Labeling.
AID1346453Human V2 receptor (Vasopressin and oxytocin receptors)1998The Journal of biological chemistry, Nov-06, Volume: 273, Issue:45
Identification of residues responsible for the selective binding of peptide antagonists and agonists in the V2 vasopressin receptor.
AID1346453Human V2 receptor (Vasopressin and oxytocin receptors)2001British journal of pharmacology, Jul, Volume: 133, Issue:5
Effects of YM471, a nonpeptide AVP V(1A) and V(2) receptor antagonist, on human AVP receptor subtypes expressed in CHO cells and oxytocin receptors in human uterine smooth muscle cells.
AID1346453Human V2 receptor (Vasopressin and oxytocin receptors)1998British journal of pharmacology, Dec, Volume: 125, Issue:7
Pharmacological characterization of the human vasopressin receptor subtypes stably expressed in Chinese hamster ovary cells.
AID1346468Rat V2 receptor (Vasopressin and oxytocin receptors)1998The Journal of biological chemistry, Nov-06, Volume: 273, Issue:45
Identification of residues responsible for the selective binding of peptide antagonists and agonists in the V2 vasopressin receptor.
AID1346432Human V1A receptor (Vasopressin and oxytocin receptors)1998British journal of pharmacology, Dec, Volume: 125, Issue:7
Pharmacological characterization of the human vasopressin receptor subtypes stably expressed in Chinese hamster ovary cells.
AID1346432Human V1A receptor (Vasopressin and oxytocin receptors)2001British journal of pharmacology, Jul, Volume: 133, Issue:5
Effects of YM471, a nonpeptide AVP V(1A) and V(2) receptor antagonist, on human AVP receptor subtypes expressed in CHO cells and oxytocin receptors in human uterine smooth muscle cells.
AID1346453Human V2 receptor (Vasopressin and oxytocin receptors)1996The Journal of clinical investigation, Dec-15, Volume: 98, Issue:12
Characterization of SR 121463A, a highly potent and selective, orally active vasopressin V2 receptor antagonist.
AID1346453Human V2 receptor (Vasopressin and oxytocin receptors)2000Kidney international, Oct, Volume: 58, Issue:4
Binding properties of a selective tritiated vasopressin V2 receptor antagonist, [H]-SR 121463.
AID1346460Human V1B receptor (Vasopressin and oxytocin receptors)2001British journal of pharmacology, Jul, Volume: 133, Issue:5
Effects of YM471, a nonpeptide AVP V(1A) and V(2) receptor antagonist, on human AVP receptor subtypes expressed in CHO cells and oxytocin receptors in human uterine smooth muscle cells.
AID1346453Human V2 receptor (Vasopressin and oxytocin receptors)1999British journal of obstetrics and gynaecology, Oct, Volume: 106, Issue:10
Receptor binding of oxytocin and vasopressin antagonists and inhibitory effects on isolated myometrium from preterm and term pregnant women.
AID1346453Human V2 receptor (Vasopressin and oxytocin receptors)2000European journal of biochemistry, Jul, Volume: 267, Issue:13
Conserved aromatic residues in the transmembrane region VI of the V1a vasopressin receptor differentiate agonist vs. antagonist ligand binding.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (95)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's11 (11.58)18.2507
2000's47 (49.47)29.6817
2010's36 (37.89)24.3611
2020's1 (1.05)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 25.68

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index25.68 (24.57)
Research Supply Index4.67 (2.92)
Research Growth Index4.56 (4.65)
Search Engine Demand Index31.58 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (25.68)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials11 (11.58%)5.53%
Reviews26 (27.37%)6.00%
Case Studies0 (0.00%)4.05%
Observational1 (1.05%)0.25%
Other57 (60.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (11)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Double-Blind, Randomized, Placebo-Controlled Multicenter Study Evaluating the Efficacy and Safety of Two Doses of Satavaptan (SR121463B) Versus Placebo in Patients With Dilutional Hyponatremia Due to the Syndrome of Inappropriate Antidiuretic Hormone Se [NCT00728091]Phase 32 participants (Actual)Interventional2008-07-31Terminated
Satavaptan in the Prevention of Ascites Recurrence: a Double-blind, Randomised, Parallel-group Comparison of Satavaptan at 5 to 10 mg Daily Versus Placebo in the Absence of Diuretics in Patients With Recurrent Ascites Due to Cirrhosis of the Liver. [NCT00366795]Phase 3241 participants (Actual)Interventional2006-08-31Terminated(stopped due to Study was terminated due to safety reason.)
Satavaptan Cirrhotic Ascites Treatment Study: a Double-blind, Randomised, Parallel-group Comparison of Treatment With Satavaptan at 5 to 10 mg Daily Versus Placebo on Top of Conventional Treatment in Patients With Ascites Due to Cirrhosis of the Liver [NCT00358878]Phase 3463 participants (Actual)Interventional2006-07-31Completed
Satavaptan in the Prevention of Ascites Recurrence: a Double-blind, Randomised, Parallel-group Comparison of Satavaptan at 5 to 10 mg Daily Versus Placebo With Concomitant Diuretics in Patients With Recurrent Ascites Due to Cirrhosis of the Liver. [NCT00359437]Phase 3501 participants (Actual)Interventional2006-07-31Terminated
Study for the Prevention of Ascites (SPA): Comparison of Fixed Doses of SR121463B Versus Placebo in the Reduction of Recurrence of Cirrhotic Ascites [NCT00501384]Phase 2151 participants (Actual)Interventional2004-04-30Completed
An Open-Label, Multicenter Study Evaluating the Long-Term Safety and Efficacy of SR121463B in Patients With Syndrome of Inappropriate Antidiuretic Hormone Secretion [NCT00264914]Phase 357 participants (Actual)Interventional2005-07-31Completed
SR121463B in Cirrhotic Ascites Treatment With Normonatraemia: A Placebo-Controlled, Dose-Comparison Study [NCT00501566]Phase 2148 participants (Actual)Interventional2004-04-30Completed
SR121463B in Cirrhotic Ascites Treatment With Hyponatraemia: A Placebo-Controlled, Dose-Comparison Study [NCT00501722]Phase 2110 participants (Actual)Interventional2004-04-30Completed
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Escalation, Multicenter Study Evaluating the Efficacy and Safety of SR121463B in Patients With Syndrome of Inappropriate Antidiuretic Hormone Secretion. [NCT00032734]Phase 235 participants (Actual)Interventional2001-06-30Completed
A Randomized, Double-Blind, Placebo-Group, Multicenter Study Evaluating the Efficacy and Safety of SR121463B in Patients With Syndrome of Inappropriate Antidiuretic Hormone Secretion [NCT00264927]Phase 377 participants (Actual)Interventional2004-05-31Completed
A Multicenter, Randomized, Placebo-Controlled, Double-Blind Trial Evaluating the Effect of a Vasopressin V2 Receptor Antagonist (SR121463B) on Serum Sodium in Patients With Dilutional Hyponatremia [NCT00274326]Phase 3150 participants Interventional2005-05-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]